Market research
AVCT.LSE Avacta Group Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 342M
- P/E ratio
- Not available
- Analyst target
- 88.45
- Dividend yield
- Not available
- Beta
- -0.11
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYYW9G87
- Market cap
- 342M
- P/E ratio
- Not available
- Analyst target
- 88.45
- Dividend yield
- Not available
- Beta
- -0.11
About
About Avacta Group Plc
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AVCT.LSE discussion.
5 years, 5 months ago
Avacta Group Plc is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 69.7.
Based on the above factors, Avacta Group Plc gets an overall score of 1/5.